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Abstract
Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe
asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway
disease. Nitrogen dioxide (NO2) is an environmental toxin that correlates with asthma severity, exacerbation, and risk
of adverse outcomes. Mice that are allergically sensitized to the antigen ovalbumin by exposure to NO2 exhibit a
mixed Th2/Th17 adaptive immune response and eosinophil and neutrophil recruitment to the airway following antigen
challenge, a phenotype reminiscent of severe clinical asthma. Because IL-1 receptor (IL-1R) signaling is critical in the
generation of the Th17 response in vivo, we hypothesized that the IL-1R/Th17 axis contributes to pulmonary
inflammation and airway hyperresponsiveness (AHR) in NO2-promoted allergic airway disease and manifests in
glucocorticoid-resistant cytokine production. IL-17A neutralization at the time of antigen challenge or genetic
deficiency in IL-1R resulted in decreased neutrophil recruitment to the airway following antigen challenge but did not
protect against the development of AHR. Instead, IL-1R-/- mice developed exacerbated AHR compared to WT mice.
Lung cells from NO2-allergically inflamed mice that were treated in vitro with dexamethasone (Dex) during antigen
restimulation exhibited reduced Th17 cytokine production, whereas Th17 cytokine production by lung cells from
recipient mice of in vitro Th17-polarized OTII T-cells was resistant to Dex. These results demonstrate that the IL-1R/
Th17 axis does not contribute to AHR development in NO2-promoted allergic airway disease, that Th17 adoptive
transfer does not necessarily reflect an endogenously-generated Th17 response, and that functions of Th17
responses are contingent on the experimental conditions in which they are generated.
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Introduction
As of 2010, the Centers for Disease Control and Prevention
reported US asthma prevalence at 1 in 12 adults, and 1 in 11
children, the highest ever documented [1]. Within the asthmatic
population, 5-7% has severe disease, which is by definition
resistant to treatment with glucocorticoids (GC) [2,3]. Despite
the relative infrequency of severe asthma, this population
represents 40-50% of asthma health care costs [2].
Furthermore, severe asthmatics are a heterogeneous
population, which likely reflects diverse underlying
pathophysiologic mechanisms [4]. This patient population could
benefit from more comprehensive clinical categorization,
including the characterization of functionally relevant
biomarkers.
Nitrogen dioxide (NO2) is a toxic byproduct of combustion, a
component of air pollution, and an endogenously-generated
mediator of inflammation [5]. Exposure to NO2 correlates with
asthma severity, disease exacerbation, risk of adverse
outcomes in asthma, and development of asthma in
adolescence [6-8]. NO2 exposure is capable of sensitizing mice
to the innocuous antigen ovalbumin (OVA) [9]. This model
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reflects the impact of short-term exposure to moderate
concentrations of NO2 in the development of inhalational
allergy, taking into account the increased resistance to NO2-
mediated inflammation of mice compared to humans [5,10].
Following challenge with OVA antigen, mice exposed to NO2
and OVA during sensitization induce pulmonary inflammation
including neutrophil and eosinophil recruitment to the airway,
the generation of a mixed Th2/Th17 adaptive immune
response, and the development of airway hyperresponsiveness
(AHR), arguably the most relevant endpoint clinically [9,11,12].
This inflammatory profile is reminiscent of that observed in
severe asthma [13].
Traditionally, asthma has been considered a Th2-mediated
disease, but other immunologic mechanisms likely contribute,
notably the Th17 adaptive immune response. Increased IL-17
can be measured from the BAL and sputum of asthmatic
subjects compared with healthy controls [14,15]. Furthermore,
IL-17 levels and increased CD4+ Th17 cells in the peripheral
blood correlate with asthma severity [16,17]. Th17 cells are a
distinct subset of CD4+ T-cells capable of producing IL-17A,
IL-17F, IL-22, and GM-CSF, which are regulated in part by the
Th17-specific transcription factor RORγt [18]. We and others
have demonstrated that IL-1R signaling is critical in the
development of Th17 responses [19-23], including that
generated in NO2-promoted allergic airway disease [11]. While
additional cell types can produce IL-17 [24], the CD4+TCRβ+
population of cells was recently identified as the relevant
IL-17A-producing cell population in NO2-promoted allergic
airway disease following antigen challenge [11].
While evidence exists indicating that IL-17A may
downregulate inflammation [25,26], IL-17A is thought to
promote asthma pathogenesis by stimulating the production of
inflammatory cytokines – including CXC chemokines capable
of recruiting neutrophils, inducing smooth muscle contraction,
increasing mucus production, and promoting GC resistance
[15,27-31]. The adoptive transfer of in vitro-polarized Th17 cells
results in neutrophilic, GC-resistant allergic airway disease
following antigen challenge, whereas pulmonary inflammation
and AHR following the adoptive transfer of Th2-polarized cells
is GC-sensitive [32]. Neutrophils contribute to asthma
pathogenesis by releasing enzymes that potentiate tissue
damage, oxidant formation, and mucus secretion [33,34]. The
recruitment of neutrophils is associated with more severe
asthma, including frequency of symptoms and reduced
pulmonary function [14].
In contrast to the Th17 response, the Th2 immune response
is characterized by eosinophil recruitment to the airway, mucus
production, increased expression of the mucin-associated
genes Gob5 and Muc5ac, and the production of Th2 and Th2-
promoting cytokines IL-4, IL-5, IL-13, and IL-25 [13,35,36]. IL-4
signaling at the time of sensitization is critical for generating the
Th2 response [37,38]. Signaling through IL-4Rα pathway
results in STAT6 phosphorylation and upregulation of the Th2-
specific transcription factor, Gata3 [39,40]. Because IL-4Rα is a
component of both the IL-4 and IL-13 receptors, mice that are
genetically deficient in STAT6 are generally unable to respond
to IL-4 and IL-13 [39].
The process of NO2-promoted allergic sensitization likely
involves downstream generation of endogenous danger-
associated molecular patterns (DAMPs) by airway epithelial
cells, activating antigen presenting cells (APCs) to produce
inflammatory mediators including activated IL-1β that results in
the development of a Th17 response [5,9,11,12,41,42]. Despite
our insight into the mechanisms required for generating the
Th17 response in NO2-promoted allergic airway disease, the
functional relevance of the Th17 response remains unclear.
Because the Th17 response is necessary and sufficient to drive
pulmonary inflammation and AHR in multiple animal models of
asthma [13,32,43], we hypothesized that the IL-1R-dependent
Th17 response in NO2-promoted allergic asthma would
contribute to pulmonary inflammation and AHR development
following antigen challenge. Given the previously observed
resistance of the Th17 response to inhibition by the GC
dexamethasone (Dex) [32], we further hypothesized that the
endogenously-generated IL-1R-dependent Th17 response in
NO2-promoted allergic airway disease would exhibit Dex
resistance. Whereas IL-17A neutralization at challenge and
genetic deficiency in IL-1R resulted in the inhibition of
neutrophil recruitment to the airway following antigen
challenge, AHR was either not affected or exacerbated. These
results are surprising, and given Th17’s pathologic role in GC
resistance, we sought to compare the endogenously-generated
Th17 response to that manifest following the adoptive transfer
of in vitro-polarized Th17 OTII T-cells. We found that the
endogenously generated Th17 response in NO2-promoted
allergic airway disease was both quantitatively and qualitatively
different from that generated following Th17 adoptive transfer,
exhibiting sensitivity to both Dex and IL-1R inhibition with
recombinant IL-1 receptor antagonist (anakinra) during ex vivo
lung restimulation in the presence of antigen. In contrast, the
Th17 response generated by lung cells from recipients of the
Th17 adoptive transfer was resistant to Dex and anakinra.
These data suggest that the adoptive transfer model for
studying Th17 responses in allergic airway disease is not
necessarily representative of the endogenously-generated
Th17 response and that the Th17 response does not represent
a single entity, but a response with functional variability that is




Female C57BL/6, IL-1R-/-, STAT6-/- (Jackson Laboratories,
Bar Harbor, ME), and female OTII transgenic mice (C57BL/6
background; bred at the University of Vermont) were 6-8 weeks
old at the beginning of experimentation. Studies were approved
by the Institutional Animal Care and Use Committee of the
University of Vermont under the permits 09-050, 12-018, and
12-020. Mice were housed in an AAALAC approved facility,
maintained on a 12-hour light/dark cycle, and were provided
food and water ad libitum. All mice were euthanized with
sodium pentobarbitol (200-300 μL by i.p. injection; Wilcox
Pharmacy, Rutland, VT) or for pulmonary function assessment,
anesthetized with 90 mg/kg sodium pentobarbital. All
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experiments were conducted with conscious effort to minimize
animal suffering.
NO2-promoted allergic sensitization and challenge
For NO2-promoted allergic sensitization, a single 1-hour
exposure to 15ppm of NO2 on day 1 was followed by 30
minutes of nebulized 1% OVA, Fraction V (Sigma-Aldrich, St.
Louis, MO) in saline, on days 1, 2, and 3 [11]. All mice were
OVA-challenged on days 14, 15, and 16, as described [41].
Analyses were performed at 48 hours after the final OVA
challenge, on day 18.
Antibody treatments
For neutralization of IL-17A, 0.5 mg of neutralizing anti-
IL-17A antibody (17F3; BioXCell, West Lebanon, NH) or IgG
isotype antibody (MOPC21; BioXCell) was administered by i.p.
injection in 500 μL saline on day 13. For inhibition of the Th2
response, 1 mg of neutralizing anti-IL-4 antibody (11B11;
BioXCell) was administered in a single i.p. injection delivered
on day 0, and some mice received an additional 1 mg of
neutralizing anti-IL-4 antibody on day 13. Control mice received
1 mg of IgG control antibody (MOPC21; BioXCell) in a single
i.p. injection in 500 μL saline on days 0 and 13.
In vitro polarization and adoptive transfer
Splenocytes and peripheral lymph nodes were harvested
from OTII transgenic mice. Single cell suspensions were
generated by passing the tissues through a 70 μm nylon mesh
filter (BD Biosciences, San Jose, CA) and lymphocytes were
enriched by centrifugation through Lymphocyte Separation
Medium (MP Biomedicals, Irvine, CA). CD4+ T-cells were
isolated via magnetic negative selection following
manufacturer’s instructions (StemCell Technologies,
Vancouver, BC). Following 3 wash steps, cells were plated at
1x106 cells/mL in CD4+ complete medium (5% FBS (Cell
Generation, Fort Collins, CO), pen/strep, L- glutamine, folic
acid, glucose, and 2-ME in RPMI-1640 (Gibco, Grand Island,
NY), containing 2 μg/mL anti-CD28; BD Biosciences) in wells
pre-coated with 5 μg/mL anti-CD3 (BD Biosciences). Th17
differentiation was performed using 10 μg/mL anti-IFNγ (R&D
Systems, Minneapolis, MN), 10 μg/mL anti-IL-4 (R&D
Systems), 30 ng/mL IL-6 (R&D Systems), 10 ng/ml IL-23 (R&D
Systems), and 1 ng/mL TGFβ (R&D Systems). Th2 T-cells
were differentiated in 10 μg/mL anti-IFNγ (R&D Systems), 30
ng/mL IL-4 (R&D Systems), and 20 units/mL IL-2 (R&D
Systems). Cell cultures were split on day 3 and resuspended in
fresh media containing appropriate polarizing and T-cell
stimulating mediators. In vitro differentiated cells were
harvested on day 6 and supernatants were validated for
appropriate cytokine production by ELISA. Washed cells were
resuspended at 1x107 cells/ml in PBS and 2x106 cells were
adoptively-transferred into the retroorbital sinus of isoflurane-
anesthetized female C57BL/6 mice. Recipient mice were
antigen-challenged immediately following adoptive transfer and
on each of the next two days for 30 minutes with aerosolized
OVA. Mice were analyzed 24 hours following the final antigen
exposure.
Assessment of airway hyperresponsiveness
Mice were anaesthetized with i.p. sodium pentobarbital
(90mg/kg), the trachea were cannulated and the mice were
connected to a flexiVent™ computer controlled small animal
ventilator (SCIREQ, QC, Canada), as previously described
[44-46]. Mice were ventilated at 200 breaths/minute and
paralyzed with an i.p. injection of pancuronium bromide (0.8
mg/kg). The animals were stabilized over about ten minutes of
regular ventilation at a positive end-expiratory pressure (PEEP)
of 3 cmH 2O. A standard lung volume history was then
established by delivering two total lung capacity maneuvers
(TLC) to a pressure limit of 25 cmH 2O and holding for three
seconds. Next, two baseline measurements of respiratory input
impedance (Zrs) were obtained. This was followed by an
inhalation of aerosolized PBS (control) for 10 seconds,
achieved by an in-line piezo electric nebulizer (Aeroneb,
Aerogen, Galway, Ireland). Zrs was then measured every 10
seconds for 3 minutes (18 measurements of Zrs in total). This
complete sequence of maneuvers and measurements was
then repeated for aerosol exposures to three ascending doses
of aerosolized methacholine. Data were fit to the single-
compartment model [47] to provide values for resistance (R),
reflecting constriction in the lungs, and elastance (E), reflecting
the elastic rigidity of the lungs. R and E are presented as the
percentage change from baseline, as measured at the
beginning of the protocol.
BAL collection and processing
Lungs were lavaged with 1 mL DPBS (Sigma-Aldrich, St.
Louis, MO). The BAL fluid was centrifuged, and the total cells
in the pellet were resuspended in PBS and enumerated by
counting with an Advia 120 Hematology System (Bayer
HealthCare, Leverkusen, Germany). Differential analysis was
performed by cytospin and H&E stain from approximately 200
cells per slide.
Preparation of lung single cell suspensions
Lung cells were prepared in the lung dissociation kit (Miltenyi
Biotec, Auburn, CA) and a GentleMACs dissociator (Miltenyi
Biotec), according to manufacturer’s instructions. Four rounds
of program m_lung_01 were used before the first incubation, a
single round of program “B” was used between incubations,
and m_lung_02 was used before lysing red blood cells with
ACK buffer (8,024 mg/l NH4Cl, 1,001 mg/l KHCO3, 7.722 mg/l
EDTA·Na2 2H2O).
In vitro antigen restimulation and cytokine quantitation
1×106 cells/ml in CD4+ complete media were activated with
400 μg/ml (unless otherwise noted) for 96 hours. Where
indicated, samples were incubated in the presence of 10-8 M
dexamethasone (Sigma, St. Louis, MO) and/or 200 ng/mL
anakinra (Biovitrum, Stockholm, Sweden). Supernatants were
analyzed by ELISA (R&D Systems) or Luminex-based
multiplex assay (Millipore, Billerica, MA).
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Quantitative RT-PCR
Total RNA was extracted from snap frozen whole lungs or
the single large lung lobe using the PrepEase RNA Isolation kit
(USB Corp., Cleveland, OH) and reverse transcribed to cDNA
using the iScript kit (Bio-Rad, Hercules, CA). Primers were






AGGACCCCAGACTGGCTAAA-3’), and Gob5 (5’-
AAGCCAACCACTCCCATGAC-3’ and 5’-
TGCGAAAGCATCAACAACAC-3’) using NCBI Primer-BLAST
and synthesized by Integrated DNA Technologies (Coralville,
IA). RT-PCR was performed using SYBR Green Supermix
(Bio-Rad) and normalized to Gapdh (5’-
ACGACCCCTTCATTGACCTC-3’ and 5’-
TTCACACCCATCACAAACAT-3’) or Actb (5’-
TCCTTCGTTGCCGGTCCACA-3’ and 5’-
CGTCTCCGGAGTCCATCACA-3’) using the ΔΔCT method, as
previously described [48].
Statistical Analysis
Data were analyzed by two-tailed unpaired student’s t-test,
one-way ANOVA, or two-way ANOVA using GraphPad Prism 4
for Mac (GraphPad Software, La Jolla, CA). Statistically
significant (p < 0.05) results by ANOVA were further analyzed
by Bonferroni or Tukey post-hoc test.
Results
IL-17A is required for airway recruitment of neutrophils
but not AHR in NO2-promoted allergic airway disease
IL-17A is recognized to promote pulmonary inflammation in
allergic airway disease [13,28,31,49]. Having previously
identified factors critical in the generation of the Th17 adaptive
immune response in NO2-promoted allergic airway disease
[11,12,41], we sought to further characterize the functional
relevance of the Th17 response in this model by first
characterizing AHR and airway inflammation. Following antigen
challenge, allergically inflamed mice demonstrated increased
total BAL cells, comprised of macrophages, neutrophils and
eosinophils (Figure 1A-D). In response to challenge with
increasing doses of methacholine (MCh), mice that had been
allergically sensitized with NO2 and antigen challenged
developed a statistically significant increase in resistance
(Figure 1E-F) and elastance (Figure 1G-H) compared to non-
inflamed control mice. Allergically sensitized mice also
demonstrated a statistically significant increase in the
expression of the neutrophil-recruiting chemokine Cxcl5 in the
lung (Figure 1I). Trends for increased neutrophil and epithelial
derived gelatinase lipocalin-2 (Lcn2; Figure 1J), the mucin-
associated gene Gob5 (Figure 1K), and the mucin gene
Muc5ac (Figure 1L) were also evident in the lungs of
allergically inflamed mice [50,51].
To address the functional contribution of IL-17A in NO2-
promoted allergic airway disease, we administered anti-IL-17A
neutralizing antibody or IgG isotype control antibody one day
prior to the first OVA challenge. IgG-treated mice that had been
allergically sensitized and antigen challenged exhibited similar
cellularity in the BAL and AHR as that of untreated NO2-
sensitzed and challenged mice. Mice that received neutralizing
anti-IL-17A antibody demonstrated no differences in total
numbers of BAL cells (Figure 1A), macrophages (Figure 1B), or
eosinophils (Figure 1D). However, the number of neutrophils in
the BAL of mice treated with anti-IL-17A was significantly
decreased in comparison to IgG-treated mice (Figure 1C).
Surprisingly, mice that were treated with anti-IL-17A
neutralizing antibody at the time of antigen challenge
developed similar resistance (Figure 1E-F) and elastance
(Figure 1G-H) to that of IgG-treated mice. While elastance that
developed in anti-IL-17A treated mice was significantly
increased over that of IgG isotype control treated mice,
elastance in anti-IL-17A treated mice was not increased above
that of untreated NO2-sensitized and challenged mice. Gene
expression analysis revealed a trend for decreased Cxcl5
(Figure 1I) and a trend for increased Gob5 expression (Figure
1K) in the lungs of anti-IL-17A treated mice, whereas Muc5ac
and Lcn2 did not differ between IgG isotype control and anti-
IL-17A treated mice. We conclude from these experiments that
while IL-17A is required for neutrophil recruitment to the airway
in NO2-promoted allergic airway disease, likely through
regulation of Cxcl5, neither IL-17A nor neutrophil recruitment to
the airway is required for AHR.
As others have reported IL-17A-dependent AHR and
pulmonary inflammation in the absence of a Th2 response [52],
we next sought to address whether IL-17A production was
sufficient to promote airway inflammation and AHR in the
setting of decreased Th2 responses. To address this
hypothesis, we inhibited the generation of a Th2 response by
administering anti-IL-4 neutralizing antibody [37,38] at the time
of sensitization in NO2-promoted allergic airway disease. In
comparison to IgG-treated mice, we quantitated increased
IL-17A and IL-17F production by lung single cell suspensions
restimulated in the presence of OVA antigen from mice that
received anti-IL-4 neutralizing antibody prior to NO2 exposure
(Figure 2A-B), whereas IL-5 and IL-13 were significantly
diminished (Figure 2C-D). We measured no differences in
IFNγ, IL-22, or GM-CSF, and IL-21 was minimally or not
detected (data not shown). These data validate the inhibition of
the Th2 response using anti-IL-4 neutralizing antibodies in our
asthma model and demonstrate that IL-4 or a mediator
controlled by IL-4 negatively regulates the production of IL-17A
and IL-17F.
Treatment with anti-IL-4 neutralizing antibody resulted in a
significant decrease in total BAL cells (Figure 2E) and
eosinophils (Figure 2H), whereas macrophages (Figure 2F)
and neutrophils (Figure 2G) were not affected. Upon
assessment of MCh responsiveness, mice that received
isotype control antibody, but not anti-IL-4 antibody, developed
elevated resistance (trend only; Figure 2I-J) and elastance
(Figure 2K-L) compared to non-inflamed mice. These data
suggest that the endogenously-generated Th17 response is not
sufficient to elicit AHR in NO2-promoted allergic airway disease.
While validating our model, we discovered that to adequately
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assess AHR in NO2-promoted allergic airway disease, MCh
must be administered up to a dose of 100 mg/mL since we did
not observe a statistically significant increase in AHR at 50
mg/mL MCh (Figure 1E-H). However, in mice treated with IgG
isotype control antibody (Figure 2L), we did observe a
significant increase in AHR at 50 mg/mL MCh, suggesting that
the IgG might elicit an effect independent of our asthma model.
Further characterization of the impact of IgG on AHR is
presented in the (Figure S1). Taken together, these data
demonstrate that in the absence of a strong Th2 response, the
potentiated production of IL-17A and IL-17F is not sufficient to
exacerbate pulmonary inflammation or AHR above that
observed in NO2-promoted allergic airway disease.
The absence of the IL-1R-dependent Th17 response in
NO2-promoted allergic airway disease correlates with
exacerbation of AHR
Th17 cells produce multiple cytokines that are known to
regulate inflammation, including IL-17A, IL-17F, IL-22, and GM-
CSF [28,53-55]. We have previously demonstrated a critical
role for IL-1R signaling in the generation of the Th17 response,
but not the Th2 response, in NO2-promoted allergic airway
disease [11]. Because neutralization of IL-17A at antigen
challenge does not protect mice against the development of
AHR (Figure 1), and the potentiation of IL-17A and IL-17F
production in the setting of a diminished Th2 response is not
sufficient to exacerbate AHR, we hypothesized that the Th17
response contributes minimally to the airway inflammation and
AHR development in our allergic asthma model. To address
the role of the IL-1R-dependent Th17 response, we subjected
C57BL/6 (WT) mice and IL-1R-/- mice to NO2-promoted allergic
sensitization and antigen challenge. We also hypothesized that
Figure 1.  IL-17A is required for airway recruitment of neutrophils but not AHR in NO2-promoted allergic airway
disease.  C57BL/6 mice were exposed to 15ppm NO2 for 1 hour on day 1. All mice were exposed to OVA on days 1-3 and again
during challenge on days 14-16. Treatment groups received either IgG isotype control antibody or anti-IL-17A neutralization
antibody one day prior to antigen challenge on day 13. 48 hours following the final antigen challenge, BAL total cells (A) were
quantified and macrophages (Macs; B), neutrophils (PMNs; C), and eosinophils (Eos; D) were calculated based on cell fractions.
Pulmonary function assessment was performed by invasive forced oscillation technique. The percent baseline and average percent
baseline per dose methacholine were calculated for resistance (R; E-F) and elastance (E; G-H), as determined by the single-
compartment model [47]. Lungs were removed and snap frozen prior to RNA analysis for Cxcl5 (I), Lcn2 (J), Gob5 (K), and Muc5ac
(L). Statistics were performed by 1-way ANOVA (A-D and I-L) or 2-way ANOVA (E-H) and Tukey post hoc analysis. **** p < 0.0001,
*** p < 0.001, ** p < 0.01, * p < 0.05 compared to non-inflamed unless indicated by brackets. ND, not significantly different from non-
inflamed. n = 7 per group (A-H) or n = 5-7 per group (I-L).
doi: 10.1371/journal.pone.0074730.g001
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the Th2 immune response is required for the generation of
AHR following antigen challenge. To address this hypothesis,
we also subjected STAT6-/- mice, which are unable to respond
to IL-4 or IL-13, to NO2-promoted allergic sensitization and
antigen challenge [39]. Our analysis revealed that total BAL cell
counts increased in WT and IL-1R-/- mice in comparison with
non-inflamed control mice and STAT6-/- mice (Figure 3A).
Whereas neutrophils and eosinophils were elevated in the BAL
of WT mice (Figure 3C-D), neutrophils in the BAL from IL-1R-/-
mice were significantly decreased compared to WT mice
(Figure 3C), while numbers of eosinophils from IL-1R-/- mice
were not significantly different from WT (Figure 3D).
Neutrophils and eosinophils in the BAL of STAT6-/- mice were
not statistically different from non-inflamed mice (Figure 3C-D).
Upon assessment of MCh responsiveness, WT mice
demonstrated a significant increase in elastance, but not
resistance, compared to non-inflamed control mice (Figure 3E-
H). Surprisingly, IL-1R-/- mice developed significantly elevated
resistance and elastance above that of WT mice, whereas
STAT6-/- mice developed AHR that was not statistically
different from WT mice (Figure 3E-H). These data demonstrate
that neither the IL-1R-dependent Th17 response nor the
STAT6-dependent Th2 response is required for the
development of AHR in NO2-promoted allergic airway disease
Figure 2.  Inhibition of the Th2 response potentiates IL-17A and IL-17F production but is not sufficient to exacerbate
neutrophil recruitment or AHR development.  Mice were exposed to 15ppm NO2 for 1 hour on day 1. All mice were exposed to
OVA on days 1-3 and again during challenge on days 14-16 and analyzed 48 hours after the final antigen challenge. IgG isotype
control antibody was administered one day prior to NO2 exposure and one day prior to OVA challenge. Anti IL-4 neutralizing
antibody was administered one day prior to sensitization on day 0. A second group also received anti-IL-4 antibody one day prior to
OVA challenge on day 13. Because we observed no differences in AHR, BAL cell counts, or cytokine production between mice that
received anti-IL-4 at sensitization only on day 0 or on day 0 and day 13, we combined anti-IL-4 treated mice for statistical analysis.
48 hours following the final antigen challenge, lungs were removed and enzymatically digested. Single cell suspensions were
restimulated in the presence of 200 μg/ml OVA antigen for 96 hours prior to the harvesting of cell supernatants and analysis of
cytokine production. IL-17A (A) and IL-17F (B) were quantitated by Milliplex. IL-5 (B) and IL-13 (C) were quantified by ELISA. BAL
total cells (E), Macs (F), PMNs (G), and Eos (H) were determined. Percent baseline and average percent baseline per dose of
methacholine were calculated for R (I-J) and E (K-L). Statistics were performed by student’s t-test (A-D), 2-way ANOVA (J and L) or
1-way ANOVA (E-H) and Tukey post hoc analysis. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to non-inflamed
unless otherwise indicated by brackets. ND, not significantly different compared to non-inflamed. n = 6-12 per group.
doi: 10.1371/journal.pone.0074730.g002
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and suggest that IL-1R signaling is protective against AHR
development in this asthma model.
To further address the mechanisms that may contribute to
increased AHR in IL-1R-/- mice following antigen challenge in
NO2-promoted allergic airway disease, we quantified gene
expression in whole lungs and cytokine production following
OVA restimulation of lung single cell suspensions from WT,
IL-1R-/-, and STAT6-/- mice. We found that the neutrophil-
activating chemokine Cxcl5, as well as Lcn2, were decreased
in both IL-1R-/- mice and STAT6-/- mice (Figure 3I and J). The
mucin-associated genes, Gob5 and Muc5ac, however, were
not statistically different between WT and IL-1R-/- mice, but
Figure 3.  The absence of the IL-1R-dependent Th17 response in NO2-promoted allergic airway disease correlates with
exacerbation of AHR.  C57BL/6 (WT), IL-1R-/-, and STAT6-/- mice were subjected to NO2-promoted allergic sensitization,
challenged, and analyzed 48 hours following the final antigen challenge. BAL total cells were quantified (A) and Macs (B), PMNs
(C), and Eos (D) were calculated based on cell fractions. Methacholine responsiveness was performed by invasive forced oscillation
technique. The percent baseline and average percent baseline per dose of methacholine were calculated for R (E-F) and E (G-H),
as determined by the single-compartment model [47]. Quantitative RT-PCR was performed to measure gene expression for Cxcl5
(I), Lcn2 (J), Gob5 (K), and Muc5ac (L). Th2 cytokines IL-4 (M), IL-5 (N), and IL-13 (O), the Th1 cytokine IFNγ (P), and the Th17
cytokines IL-17A (Q), IL-17F (R), IL-22 (S), and IL-21 (T) were quantified by Milliplex. The dashed line in M, S, and T signifies the
lower limit of detection in the assay. Statistics were performed by 1-way ANOVA (A-D and I-T) or 2-way ANOVA (F and G) and
Tukey post-hoc analysis. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to non-inflamed unless otherwise indicated
by brackets. n = 5-8/group.
doi: 10.1371/journal.pone.0074730.g003
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were decreased in STAT6-/- mice (Figure 3K and L). Following
the restimulation of lung single cell suspensions in the
presence of antigen, the production of Th2 cytokines IL-4, IL-5,
and IL-13 were increased in IL-1R-/- mice compared to WT or
STAT6-/- mice (Figure 3M-O). In contrast, IL-17A and IL-17F
production were decreased in IL-1R-/- mice and STAT6-/- mice
compared to WT mice (Figure 3Q-R). A similar trend existed for
IFNγ (Figure 3P) and minimal amounts of IL-21 and IL-22 were
detected (Figure 3S-T). Overall, these data suggest that the
IL-1R/Th17 axis may inhibit the Th2 adaptive immune response
in NO2-promoted allergic airway disease at the time of antigen
challenge.
IL-17A production by lung cells from NO2-allergically
sensitized mice is qualitatively different from that of
Th17-transferred mice
The adoptive transfer of in vitro polarized effector T-cells is a
method for investigating the in vivo consequences of an
antigen-specific immune response [32]. The observation that
IL-17A, neutrophils, and the Th17 response do not contribute to
AHR in our asthma model clearly contrasts with that observed
from a model in which adoptive transfer of in vitro polarized
Th17 OTII T-cells is followed by antigen challenge [32]. To
better understand the Th17 response generated endogenously
in NO2-promoted allergic airway disease, we compared it to the
responses generated following adoptive transfer of antigen-
specific Th17 or Th2 cells followed by OVA challenge.
Single-cell suspensions of lungs from NO2-sensitized and
challenged mice (bars labeled “None”, Figure 4A-D) produced
IL-17A, IL-5, IL-13, and IFNγ upon in vitro restimulation,
whereas recipient mice of the Th17 adoptive transfer produced
10-fold more IL-17A, similar levels of IL-5 and IL-13, and 20-
fold more IFNγ (bars labeled “None”, Figure 4E-H). These data
indicate that the endogenously-generated Th17 response in
NO2-promoted allergic airway disease is of decreased
magnitude compared to that generated following adoptive
transfer of in vitro polarized Th17 OTII T-cells. Restimulated
lung cells from Th2-transferred mice produced much higher
levels of the Th2 cytokines IL-5 and IL-13 than either NO2-
allergically inflamed mice or mice that had received Th17 cells,
whereas IL-17A production was 10-fold less than that of the
NO2-allergically inflamed mice and 100-fold less than Th17
adoptively transferred mice, and IFNγ production was 10-fold
greater than that of the NO2-allergically inflamed mice and 2-
fold less than Th17 adoptively transferred mice (bars labeled
“None”, Figure 4I-L).
The Th17 response generated upon adoptive transfer results
in GC-resistant allergic airway disease, whereas the Th2
adoptive transfer is GC-sensitive [32]. Since IL-17A production
and neutrophils, which are thought to promote resistance to GC
treatment [30,56], are present in our model following antigen
challenge, we sought to contrast the relative GC sensitivity of
the Th17 response in NO2-promoted allergic airway disease to
that in the Th17 and Th2 adoptive transfer models. The in vitro
polarization of Th17 T-cells does not require IL-1R signaling
[19], which contrasts with the IL-1R-dependent Th17 response
in NO2-promoted allergic airway disease [11]. Furthermore,
IL-1R signaling is an attractive therapeutic target in the
treatment of clinical asthma [57-59]. However, it remains
unknown whether the Th17 immune response generated at
antigen challenge, a clinically relevant time point, requires
IL-1R signaling. We applied an ex vivo approach to address the
GC sensitivity of the endogenously-generated Th17 response
at antigen challenge and to test whether the antigen-specific
Th17 response in the lung requires IL-1R signaling. Following
antigen challenge in either NO2-promoted allergic sensitization
or the adoptive transfer of in vitro polarized Th17 or Th2 OTII
T-cells and antigen challenge, we incubated lung single-cell
suspensions with the IL-1 receptor antagonist anakinra, the GC
dexamethasone (Dex), the combination, or no inhibitors in the
presence of OVA antigen. Sensitivity to either Dex or anakinra
was defined as ≥50% decrease in cytokine production
compared to lung cells from similarly-treated mice incubated in
the presence of OVA alone. Synergistic inhibition by the
combination of anakinra and Dex was defined as ≥50%
decrease in cytokine production compared with lung cells from
similarly treated mice that were incubated with OVA and either
Dex or anakinra.
In NO2-promoted allergic airway disease, IL-17A production
by OVA-restimulated lung single cell suspensions was almost
completely inhibited by either anakinra or Dex treatment, and
the combination completely inhibited production of IL-17A
(Figure 4A). In contrast, lung cell production of the Th2
cytokines IL-5 and IL-13 was resistant to anakinra treatment
(Figure 4B-C). Dex treatment completely inhibited Th2 cytokine
production, which was not further diminished by the addition of
anakinra (Figure 4B-C). The Th1 cytokine IFNγ was inhibited
by either Dex or anakinra treatment (Figure 4D). IL-17A
production by antigen-restimulated lung cells generated from
recipients of in vitro polarized Th17 cells decreased
significantly but not ≥50% in the presence of anakinra but not
Dex. The combination of Dex and anakinra further decreased
IL-17A production, although the levels remained ≥50% of
cytokine production by OVA-stimulated lung cells in the
absence of inhibitors (Figure 4E). Production of IL-5 and IFNγ
were significantly decreased when lung cells from Th17-
transferred mice were restimulated with OVA in the presence of
anakinra, although this decrease was less than 50% of the IL-5
or IFNγ production by lung cells restimulated in the presence of
OVA alone (Figure 4F, 4H). IL-5 and IFNγ production by lung
cells from recipients of Th17 cells were sensitive to Dex
treatment (Figure 4F, 4H), whereas IL-13 was sensitive to both
anakinra and Dex (Figure 4G). We conclude that endogenous
IL-17A production in NO2-promoted allergic airway disease is
sensitive to both anakinra and Dex, whereas Th2 cytokines
IL-5 and IL-13 are sensitive to Dex but not anakinra (results
summarized in Table 1). In contrast, Th17 adoptive transfer
results in IL-17A production that is resistant to Dex, anakinra,
or the combination of anakinra and Dex, and Th2 cytokine
production that demonstrates Dex sensitivity with variable
sensitivity to anakinra that is cytokine-dependent.
It is possible that the relative resistance of IL-17A production
to in vitro treatment with Dex or anakinra is a property of
polarization in an in vitro system, and that established effector
IL-17A-producing cells are resistant to inhibition by Dex, similar
to that hypothesized by others [60]. Notably, we also observed
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IL-17A production by antigen-restimulated lung cells from
recipient mice of in vitro polarized OTII Th2 cells following
antigen challenge (Figure 4I). We therefore tested the in vitro
Dex or anakinra sensitivity of OVA-restimulated lung cells from
mice that received in vitro polarized OTII Th2 cells. Similar to
that observed in NO2-allergically inflamed mice, but distinct
from that observed in Th17 adoptively transferred mice, IL-17A
production by lung cells from Th2-transferred mice was almost
completely inhibited in the presence of anakinra or Dex (Figure
4I). Production of the Th2 cytokines IL-5 and IL-13, as well as
the Th1 cytokine IFNγ, were resistant to treatment with
anakinra, but susceptible to inhibition by Dex (Figure 4J-L).
Thus, the in vitro treatment of lung cells from recipients of the
Th2 adoptive transfer exhibited anakinra and Dex sensitivity
similar to that of the NO2-promoted, endogenously generated
immune response, which is in contrast to the resistance of
IL-17A production to treatment with Dex and anakinra from
recipients of the Th17 adoptive transfer. These results indicate
that there are consequences of in vitro polarization or
characteristics of OTII cells that do not reflect the observed
resistance of IL-17A production to anakinra or Dex treatment
during antigen-restimulation of lung cells from Th17 adoptively-
transferred mice.
Figure 4.  IL-17A production by lung cells from NO2-promoted and allergically sensitized mice is qualitatively different from
IL-17A production by lung cells following Th17 adoptive transfer and antigen challenge.  Mice were subjected to NO2-
promoted allergic sensitization, OVA-challenged, and analyzed 48 hours after the final antigen challenge. For adoptive transfer,
CD4+ T-cells from OTII splenocytes by were either Th2 or Th17 polarized in vitro and adoptively transferred to recipient mice, which
were then OVA-challenged for 3 consecutive days and analyzed 24 hours following the final OVA challenge. At analysis, lungs were
removed and enzymatically digested. Lung single cell suspensions were restimulated with OVA antigen in the presence or absence
of anakinra (Ana; 0.2 μg/mL), Dex (10-8 M), or anakinra and Dex in combination for 96 hours. Cell supernatants from antigen-
restimulated and treated lung cells from mice subjected to NO2-promoted allergic sensitization and OVA challenge (A-D), Th17
adoptive transfer (E-H), or Th2 adoptive transfer (I-L) were harvested and cytokine levels were quantitated by ELISA. Statistics were
performed by one-way ANOVA and Bonferroni post hoc analysis. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to
controls (None) unless otherwise indicated by brackets. ND, not significantly different compared to controls. For NO2/OVA sensitized
and challenged mice, n = 6. For Th17 and Th2 adoptively transferred mice, samples from n = 3 mice were pooled prior to in vitro
culturing, which was performed in triplicate. Adoptive transfer data are representative of 2 independent studies.
doi: 10.1371/journal.pone.0074730.g004
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Inhibition of the Th2 response does not confer
anakinra- or Dex-resistant IL-17A production in NO2-
promoted allergic airway disease
In addition to IL-17A, the Th2 cytokine IL-4 is capable of
regulating the expression of the GC receptor and may impact
GC responsiveness [59]. Since the presence of a Th2
response can dampen IL-17A production (Figure 2A and E
[52]), we reasoned that the relative absence of the Th2
response in the Th17 adoptive transfer model compared with
that generated during NO2-promoted allergic airway disease
(Figure 4B-C versus 4F-G) may explain the differences in
sensitivity to treatment with Dex and anakinra during in vitro
restimulation. Therefore, we administered anti-IL-4 or IgG
isotype control antibody prior to NO2 sensitization and antigen
challenge, as in Figure 2. In vivo administration was followed
by the pharmacologic treatment of lung cells restimulated in the
presence of OVA antigen with either anakinra, Dex, or the
combination of anakinra and Dex. The anakinra dose used in
this experiment was 1 μg/mL, which was higher than that used
for the studies presented in Figure 4. However, incubation with
increasing doses of anakinra did not further inhibit IL-17A or
IL-5 production by lung cells from recipient mice of the Th17
adoptive transfer during antigen-restimulation (Figure S2). In
both IgG and anti-IL-4 treated mice, IL-17A levels were
significantly inhibited with either Dex or anakinra (Figure 5A
and E). In addition, IL-17A was further decreased by the
combination of anakinra and Dex in anti-IL-4 treated mice. In
both IgG and anti-IL-4 treated mice, IL-5 and IL-13 production
were unaffected by in vitro treatment with anakinra, whereas
Dex significantly inhibited the production of these Th2






















IL-17A S S S R R S S S R S S S
IL-17F S S S R R S NM NM NM NM NM NM
IL-21 ND ND ND R R R NM NM NM NM NM NM
IL-22 S S S R R S NM NM NM NM NM NM
GM-
CSF S S R S S R NM NM NM NM NM NM
IL-5 R S R R S R R S R R S R
IL-13 R S R S S R R S R R S R
IFNγ S S R R S R R S R S S S
S, sensitive; R, resistant; NM, not measured; ND, not detected GM-CSF,
granulocyte-macrophage colony-stimulating factor.
Sensitivity to dexamethasone (Dex) or anakinra (Ana) is defined as ≥ 50%
decrease in cytokine production in comparison to the appropriate antigen-
restimulated control.
* Cases in which the cytokine is Dex sensitive, addition of anakinra further
decreased the production by ≥ 50%.
doi: 10.1371/journal.pone.0074730.t001
cytokines (Figure 5B-C and Figure 5F-G). IFNγ levels in both
IgG and anti-IL-4 treated mice decreased in the presence of
either anakinra or Dex (Figure 5D and Figure 5H). Thus, the
endogenously-generated Th17 response remained sensitive to
both anakinra and Dex treatment when IL-4 was neutralized in
vivo. The residual Th2 response in anti-IL-4 treated mice
remained sensitive to Dex treatment during in vitro
restimulation of lung cells in the presence of OVA antigen
(summarized in Table 1). Thus, the potentiated production of
IL-17A and IL-17F during Th2 inhibition exhibits similar Dex
and anakinra sensitivity as IgG control antibody treated mice.
We therefore conclude that Th2 interactions with the Th17
response do not impact the Dex/anakinra sensitivity profile.
The endogenously-generated Th17 response in NO2-
promoted allergic airway disease is distinct from the
Th17 response generated following Th17 adoptive
transfer
We next addressed whether the broader Th17 response
manifest in NO2-promoted allergic airway disease and Th17
adoptive transfer demonstrated the qualitative differences in
Dex and anakinra sensitivity exhibited by the production of
IL-17A (Figure 4A and 4E). Therefore, we quantified Th17
cytokine production by lung cells restimulated with OVA
antigen in the presence or absence of anakinra and Dex
treatment following NO2-promoted sensitization and antigen
challenge (Figure 6A-D) or the Th17 adoptive transfer and
antigen challenge (Figure 6E-H). Lung cells restimulated in the
presence of antigen and either anakinra or Dex from NO2-
allergically inflamed mice produced less IL-17F (Figure 5A),
IL-22 (Figure 5B), and GM-CSF (trend only; Figure 5D) than
when restimulated in the absence of inhibitors. No IL-21 was
detected from restimulated lung cells in NO2-promoted allergic
airway disease (Figure 5C). The diminution of IL-17F, IL-22,
and GM-CSF was greater than 50% for either Dex or anakinra
treatment, which was further diminished with the combination
of anakinra and Dex. Therefore, Th17 cytokines from NO2-
allergically inflamed mouse lungs are sensitive to both anakinra
and Dex treatment in vitro (results summarized in Table 1).
For lung single-cell suspensions from Th17-adoptively
transferred mice, the production of IL-17F was not affected by
Dex, and a statistically significant decrease was observed for
the combined treatment of Dex and anakinra (Figure 6E).
Despite this decrease the levels of IL-17F remained greater
than 50% of IL-17F production from lung cells stimulated with
OVA. A slight decrease in IL-22 was observed with Dex
treatment, which was substantially potentiated and achieved
≥50% reduction by the addition of anakinra (Figure 5F),
whereas IL-22 production by lung cells treated with Dex alone
remained ≥50% of the IL-22 production by otherwise untreated
OVA-restimulated lung cells. No difference for IL-17F or IL-22
was observed upon in vitro treatment with anakinra (Figure 5E-
F). Similar to that observed in the NO2 allergically inflamed
mice, IL-21 was not detected in lung cells restimulated in the
presence of OVA alone (Figure 6G). However, in vitro
treatment with Dex during antigen restimulation of lung cells
from recipients of the Th17 adoptive transfer resulted in
increased IL-21 production (trend only), and a statistically
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significant increase in IL-21 production with the combination of
Dex and anakinra (Figure 5G). The production of GM-CSF by
lung cells from Th17-transferred mice decreased upon in vitro
treatment with Dex or anakinra (Figure 6H). In summary,
production of IL-17F (Figure 5E) and IL-22 (Figure 5F) by
antigen-restimulated lung cells from Th17 adoptively
transferred mice are resistant to treatment with either Dex or
anakinra alone. These cytokines exhibit the same Dex and
anakinra resistance as IL-17A production by lung cells from
Th17 adoptive transfer mice (Figure 3E). In contrast, GM-CSF
is inhibited by Dex and anakinra treatment. Interestingly, Dex
or the combination of Dex and anakinra induce the production
of IL-21. In comparison, the endogenously-generated Th17
response in NO2-promoted allergic airway disease is sensitive
to in vitro treatment with anakinra or Dex. These results
demonstrate that cytokine production by the endogenously-
generated Th17 response in NO2-promoted allergic airway
disease is sensitive to Dex and IL-1R-dependent during ex vivo
antigen restimulation, whereas the Th17 immune response
following the adoptive transfer of in vitro polarized Th17 cells is
Dex resistant and independent of IL-1R signaling. Therefore,
we conclude that the endogenously generated Th17 response
in NO2-promoted allergic airway disease is qualitatively distinct
from that generated following Th17 adoptive transfer and
antigen challenge.
Discussion
The Th17 response has been implicated in promoting
glucocricoid-resistant asthma and allergic airway disease
[16,17,32]. Clinical data also support a role for IL-1R signaling
in asthma [14,61-64]. As such, the IL-1R-Th17 axis is an
attractive therapeutic target for study in animal models of
allergic airway disease and, more importantly, in human
asthma [57,65]. Here we investigated the functional role of the
IL-1R-dependent Th17 response in NO2-promoted allergic
airway disease, demonstrating that while IL-17A and IL-1R are
critical in neutrophil recruitment, both are dispensable for
promoting AHR. Furthermore, our data indicate that IL-1R is
protective in AHR development and associates with diminished
Th2 responses in NO2-promoted allergic airway disease. These
results illustrate a very different function of the endogenously-
generated Th17 response in NO2-promoted allergic airway
disease than that observed following the adoptive transfer of in
vitro polarized Th17 cells. We observed in the NO2 model that
Th17 cytokine production by lung single cell suspensions
restimulated in the presence of OVA antigen was sensitive to
inhibition by either anakinra or Dex treatment. In contrast, lung
cells from mice that received in vitro polarized Th17 OTII T-
cells upon adoptive transfer and were subsequently challenged
with OVA demonstrated resistance to treatment with anakinra
or Dex. This qualitative difference is not entirely explained by
differences in magnitude or by the absence of a Th2 response
Figure 5.  Inhibition of the Th2 response with anti-IL-4 antibodies does not confer anakinra or Dex resistance in IL-17A
production by antigen-restimulated lung cells in NO2-promoted allergic airway disease.  Mice were treated as in Figure 2.
Lung single cell suspensions were restimulated with OVA antigen in the presence or absence of anakinra (Ana; 1 μg/mL), Dex (10-8
M), or anakinra and Dex in combination for 96 hours. Cell supernatants from antigen-restimulated and treated lung cells from IgG
isotype control treated mice (A-D) or anti-IL-4 treated mice (E-H) were analyzed for cytokines by ELISA. Statistics were performed
by one-way ANOVA and Bonferroni post hoc analysis (E-L). **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to
controls (none) unless otherwise indicated by brackets. ND, not significantly different compared to controls. n = 6-12 per group.
doi: 10.1371/journal.pone.0074730.g005
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in the adoptive transfer model. Taken together, our data
support a nonpathogenic and potentially protective role for the
endogenously-generated Th17 adaptive immune response in
NO2-promoted allergic airway disease, which is IL-1R-
dependent and sensitive to inhibition by Dex treatment during
antigen restimulation ex vivo. Furthermore, these results
demonstrate that Th17 adoptive transfer does not recapitulate
the Th17 response generated endogenously in NO2-promoted
allergic airway disease. The mechanisms that govern these
differences remain to be determined.
IL-17A is thought to promote airway inflammation by inducing
the production of chemokines by epithelial cells, endothelial
cells, smooth muscle cells, and fibroblasts [15,55,66].
Furthermore, in allergic airway disease, IL-17A is the Th17
cytokine implicated in AHR [13,28,32] and airway remodeling
[49]. Th17-mediated allergic airway disease acts through
IL-17A/IL-17R signaling to recruit neutrophils, and both IL-17A
and neutrophils are required to promote AHR development
[13,18,32]. Therefore, we sought to address specifically
whether IL-17A was required for AHR in our model of NO2-
promoted allergic airway disease.
Similar to our previous reports [9,11,12], we clearly observed
mixed Th2/Th17 airway inflammation, including the recruitment
of neutrophils and eosinophils, in NO2-promoted allergic airway
disease. Neutrophil recruitment required IL-17A, likely through
the induction of Cxcl5 by pulmonary epithelial cells [67],
validating that IL-17A is a critical contributor to airway
neutrophila in NO2-promoted allergic airway disease [68].
However, contrary to our hypothesis, treatment with an IL-17A-
neutralizing antibody did not impact the development of MCh
hyperresponsiveness compared to untreated NO2-sensitized
and challenged mice and resulted in increased elastance
compared to mice administered and isotype control antibody.
We have previously noted a trend for decreased neutrophils in
IL-1R-/- mice [11], and in these studies, we observed a
significant diminution of neutrophils in NO2-promoted allergic
airway disease following antigen challenge. Yet surprisingly,
IL-1R-/- mice developed exacerbated AHR compared with WT
mice.
Neutrophil activity is thought to mediate asthma by inducing
structural damage via the release of enzymes from granules
[33,69]. In a model of alum/OVA allergic airway disease,
inhibition of neutrophil elastase prevented AHR, mucus
production, eosinophil recruitment to the airway, and Th2
cytokine production, as well as eotaxin in the BAL, supporting a
role for neutrophil elastase in the generation of Th2 responses
as well [70]. In contrast, a study conducted in an alum/OVA
model demonstrated that the inhibition of neutrophils by
blocking IL-1R signaling early during antigen challenge did not
impact the development of AHR [71]. We also observed that
Figure 6.  The endogenously-generated Th17 response in NO2-promoted allergic airway disease is qualitatively different
from the Th17 response generated following Th17 adoptive transfer.  Mice were treated as in Figure 4. Lung single-cell
suspensions were restimulated with OVA antigen in the presence or absence of anakinra (Ana; 0.2 μg/mL), Dex (10-8 M), or
anakinra and Dex in combination for 96 hours. Cell supernatants of antigen-restimulated and treated lung cells from mice subjected
to NO2-promoted allergic sensitization and OVA challenge (A-D) or Th17 adoptive transfer (E-H) were analyzed for the production of
cytokines by Milliplex. Statistics were performed by 1-way ANOVA and Bonferroni post hoc analysis. **** p < 0.0001, *** p < 0.001,
** p < 0.01, * p < 0.05 compared to controls (None) unless otherwise indicated by brackets. ND, not significantly different compared
to controls. For NO2/OVA sensitized and challenged mice, n = 6. For Th17 and Th2 adoptively transferred mice, samples from n = 3
mice were pooled prior to in vitro culturing, which was performed in triplicate.
doi: 10.1371/journal.pone.0074730.g006
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inhibition of neutrophil recruitment with either anti-IL-17A
neutralizing antibody, or through genetic deficiency in IL-1R,
provided no protection against AHR in our asthma model.
Thus, our results do not support a role for IL-17A or neutrophil
recruitment in the development of AHR in NO2-promoted
allergic sensitization.
We have not detected elastase activity at the time of analysis
in either BAL cells or BAL fluid, although incubating BAL cells
for 24h at RT resulted in elastase activity (data not shown),
suggesting that the neutrophils recruited to the lavageable
airspaces in our model at the time of analysis are inactive.
Furthermore, we have conducted antibody-mediated neutrophil
depletion at the time of antigen challenge in our model and
found substantial variability in its effect on AHR.
The involvement of the IL-1R in promoting Th17 responses
that then regulate AHR development have not to our
knowledge been published. Toluene diisocyanate-mediated
AHR and mucus production required IL-1R signaling, but IL-17
was not measured in this model [72]. In HDM-promoted allergic
airway disease and an alum-independent model involving
intraperitoneal OVA injection, IL-1R was required for the
development of a Th2 response [53,73]. In NO2-promoted
allergic airway disease, the IL-1R is critical for the Th17
response but not the Th2 response [11]. Whereas the IL-1R-
dependent Th17 response has been implicated in experimental
allergic encephalomyelitis (EAE) susceptibility [23], its
importance has also been a subject of debate since IL-17A-/-,
IL-17F-/-, and IL-17A overexpressing mice were equally
susceptible to develop EAE and had similar disease severity,
whereas minimal protection was elicited by anti-IL-17A
treatment of IL-17F-/- mice [74]. Absence of a role for the Th17
response was also recently identified in an alum/OVA model of
allergic airway disease [75]. In agreement with these findings,
our results demonstrate that neutralization of IL-17A at the time
of challenge clearly does not prevent the induction of AHR in
NO2-promoted allergic airway disease.
In a number of studies, IL-17A was found to be protective in
the setting of allergic airway disease. In an alum/OVA model,
administration of IL-17A at the time of challenge decreased
AHR, eosinophils in the BAL, as well as cellular infiltrate and
mucus on histology, whereas anti-IL-17A exacerbated these
parameters [26]. In a model of RSV-promoted asthma
exacerbation, IL-17A-/- mice exhibited increased AHR despite
a decrease in neutrophils, demonstrating a protective role for
IL-17A [25]. In these models, IL-17A acts as a negative
regulator of the Th2 immune response, resulting in decreased
inflammation and diminished AHR. Administration of anti-
IL-17A neutralizing antibody had no effect on eosinophil
recruitment or Th2 cytokine responses on antigen restimulation
of lung cells in our model of NO2-promoted allergic airway
disease. While we observed a trend for increased Gob5
expression in the lungs of mice that had been treated with anti-
IL-17A antibody prior to antigen challenge, we did not observe
the same trend in IL-1R-/- mice. Thus, IL-17A does not
influence Th2 responses in our model. In contrast, IL-1R-/-
mice developed exacerbated AHR compared to WT mice,
suggesting a protective role for the IL-1R-dependent Th17
response in NO2-promoted allergic airway disease.
Interestingly, while we observed no differences in eosinophil
recruitment or the expression of mucin-associated genes, lung
cells from IL-1R-/- produced elevated levels of Th2 cytokines
following restimulation in the presence for OVA antigen. IL-13
is sufficient to elicit AHR [24] and may be the cytokine
responsible for exacerbation of this endpoint in IL-1R-/- mice in
NO2-promoted allergic airway disease.
Previous studies support the prevailing notion that either the
Th2 or the Th17 immune response is sufficient to drive
pulmonary inflammation and AHR in allergic airway disease
[18,32]. For example, IL-4/IL-13 double knockout mice exhibit
IL-4-dependent exaggerated IL-17 production, and despite
decreased eosinophils and mucus production, these mice
developed AHR similar to WT mice, which could be inhibited by
administration of an anti-IL-17A antibody [52]. Such findings
prompted us to test the hypothesis that the Th17 response in
the absence of a Th2 response is sufficient to elicit pulmonary
inflammation and AHR in NO2-promoted allergic airway
disease. Following antigen challenge, we also observed
increased IL-17A and IL-17F, but not IL-22, production by lung
cells from anti-IL-4 treated mice restimulated in the presence of
antigen. This is an important distinction since IL-17A and
IL-17F can function redundantly to promote inflammation,
whereas IL-22 can negatively regulate inflammation in allergic
airway disease [54,76]. Thus, inhibition of the Th2 response by
the administration of anti-IL-4 neutralizing antibody upregulates
the inflammatory cytokines thought to mediate inflammation,
while not impacting the production of the anti-inflammatory
cytokine IL-22 [54,76]. AHR in anti-IL-4 treated mice is not
statistically different from non-inflamed mice, whereas IgG
treated mice exhibit robust AHR responses above that of non-
inflamed and anti-IL-4 treated mice. These data indicate that
the Th17 response is not sufficient to drive AHR. However, in
control experiments, we also noted that administration of IgG
isotype control antibody at sensitization in combination with
NO2 exposure resulted in the development of more substantial
AHR than that observed in otherwise untreated mice subjected
to the NO2-promoted allergic airway disease model.
Importantly, we did not observe any effect on AHR by IgG
isotype control antibody when administered at the time of
antigen challenge. Because of the IgG effect, however, we
cannot conclude that inhibition of the Th2 response is
completely protective in this model, since we do observe a
small trend for increased elastance in anti-IL-4 treated mice
compared to non-inflamed mice. Nonetheless, it is evident that
the exaggerated production of IL-17A and IL-17F is not
sufficient to exacerbate AHR above that observed in NO2-
promoted allergic airway disease.
Because STAT6 is required for both the development and
the effector function of the Th2 response [31,77], we subjected
STAT6-/- mice to NO2-promoted allergic sensitization and
antigen challenge to determine the role of the Th2 response in
this model. In an LPS model of allergic sensitization, STAT6
was required for eosinophils and neutrophils in the airway and
AHR following antigen challenge [13]. Similarly, we observed a
complete absence of eosinophils and neutrophils in the BAL of
STAT6-/- mice. As expected, we also observed diminution of
Th2 cytokines following the restimulation of lung cells in the
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presence of OVA antigen. In contrast with the LPS sensitizing
scheme, STAT6-/- mice developed comparable AHR to that of
WT mice. Differences in experimental protocol may account for
this discrepancy. Alternatively, STAT6 can promote a
population of Treg cells, and FOXP3+ Treg cells from OVA-
tolerized mice can undergo cell division upon restimulation in
the presence of OVA [39,60]. Thus, the absence of a Treg
population may explain increases in AHR in STAT6-/- mice
despite evidence that effector T-cell populations are absent.
Others have demonstrated that inhibiting the IL-4R-STAT6
pathway may not be sufficient to inhibit alternative pathways
capable of promoting AHR [31,78]. In a chronic inhalation
model, airway inflammation and AHR in STAT6-/- mice
coincided with a switch to a Th1 response [79]. However, we
observed minimal IFNγ production in lung restimulation assays.
RSV-induced IL-17A was able to elicit mucus metaplasia in the
absence of STAT6, and in vitro, IL-17A was sufficient to induce
mucus secretion in STAT6-/-, but not in WT, tracheal epithelial
cells, suggesting that STAT6-/- is a negative regulator of Th17-
promoted inflammation and that IL-17 may promote mucus
production in the absence of a Th2 response [31]. Notably,
these results were reported from an adoptive transfer model,
which we propose may function differently than an
endogenously-generated Th17 response [60]. We observed
substantial attenuation of the Th17 response in STAT6-/- mice
and mucin gene expression was comparable to that of non-
inflamed mice. Similarly, Cxcl5 and Lcn2 expression were
decreased, which support the absence of a Th17 response.
This finding contradicts the concept that generation of a Th17
response is independent of or negatively-regulated by STAT6
[40,80]. There is evidence for Th2 cells to produce Th17
cytokines [81]. A population of memory Th2 cells in humans
and mice was identified that produces IL-17 and coexpresses
GATA3 and RORγt [81]. Whereas adoptive transfer of IL-17+
Th2 cells elicited responses similar to the combined adoptive
transfer of Th2 and Th17 cells, synergistically increasing
inflammation [81,82], we observed no evidence for synergistic
interplay of the Th17 and the Th2 response in driving NO2-
promoted allergic airway inflammation.
In our studies, NO2 allergically inflamed and challenged
STAT6-/- mice were essentially absent of airway inflammation,
despite the development of AHR. Others have also observed
the uncoupling of the immune response with AHR [13,77,83]. In
these studies, we observed that gene expression of defensins
(Defb1, Defb2, Defb3, Defb4), A20, Nox4, S100a9, Brp-39,
Chia did not correlate with AHR development following NO2-
promoted allergic airway disease (data not shown). We have
previously reported Saa3 as a candidate mediator of Th17
response induction [41] and AHR exacerbation [5]. While we
observed an increase in Saa3 expression following antigen
challenge in NO2-promoted allergic airway disease, we
observed a significant diminution of Saa3 expression in
allergically sensitized and challenged IL-1R-/- mice compared
to WT mice, indicating that Saa3 expression is not required for
AHR development and suggesting that SAA3 was not
responsible for exacerbated AHR in IL-1R-/- mice. We have
previously reported that activation in the airway epithelium of
the transcription factor NF-κB is not required for the
development of AHR despite potently modulating airway
inflammation [42]. These results suggest that mechanisms
driving AHR exist that are independent of conventional
immune-mediated inflammation. Although not studied by us,
alterations in neural signaling provide another potential non-
immune regulatory system controlling smooth muscle
contractility [84-86]. In addition, certain mouse strains have
been demonstrated to be more appropriate for measurements
of AHR, particularly in response to IL-17A, and C57BL/6 mice
are amongst the poorest strains in which to study this response
[43,87].
The adoptive transfer of in vitro polarized Th17-cells is a
conventional approach to studying the Th17 immune response
in vivo and assumes that the inflammatory response following
antigen challenge will recapitulate the antigen-specific,
endogenously-generated response. This Th17 adoptive
transfer model was used to demonstrate the critical nature of
Th17 in glucocorticoid-resistant allergic airway disease [32] We
therefore sought to compare the in vivo generated immune
response in NO2-promoted allergic airway disease to that
generated following the adoptive transfer of OVA-specific in
vitro polarized Th17 cells. We first observed that the magnitude
of the inflammatory response induced following adoptive
transfer much greater than that elicited by the endogenous
Th17 response in NO2-promoted allergic airway disease. It has
been reported that the adoptive transfer of Th17 in vitro
polarized D011.10 cells are capable of inducing the production
of IL-13 following antigen challenge in vivo [31]. The cytokine
induction upon restimulation of lung cells in the presence of
OVA was between 3-fold to 10-fold for Th17 cytokines following
Th17 adoptive transfer and 6-fold to 30-fold higher for Th2
cytokines following Th2 adoptive transfer, indicating that the
potential cytokine production in vivo following adoptive transfer
is substantially higher in comparison to the endogenously-
generated Th17 and Th2 responses. This can easily be
explained by the fact that OTII cells all express an OVA-
specific TCR, and thus every cell is potentially activated,
whereas the number of OVA-specific CD4+ T cells generated
endogenously is much smaller. However, this observation does
not address the discrepancies we uncovered in the sensitivity
to Dex and anakinra between Th17 adoptive transfer and NO2-
promoted allergic airway disease. For example, we observed
no evidence that increasing the in vitro dose of anakinra
resulted in further diminution of IL-17A or further suppression
by Dex (Figure S2A). Considering that anakinra is a
competitive antagonist of IL-1R ligand binding [88], the
resistance observed following Th17 adoptive transfer cannot be
explained by magnitude alone.
In agreement with previous reports [18,32], we observed that
IL-17 production ex vivo by lung cells following Th17 adoptive
transfer and antigen challenge was resistant to inhibition by
Dex, whereas IL-17 production by lung cells from mice
sensitized by NO2 was Dex-sensitive. This distinction
demonstrates substantial differences in the behavior of the
Th17 response between these models. In a model of allergic
airway disease in which mice were sensitized via a mucosal
route, the endogenously-generated Th17 response exhibited
Dex sensitivity under conditions of chronic antigen challenge, in
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contrast to Dex-resistant in vitro polarized OTII Th17 cells [60].
The authors attribute the in vivo Dex sensitivity to inhibition of
Th17 cell expansion, whereas established Th17 effector cells
may be Dex resistant [60]. Because our system tested lung
cells following OVA challenge, we expect that resident
lymphocytes at the time point analyzed included antigen-
specific effector T-cells that had been recruited to the lung as a
consequence of antigen challenge. Thus, the observed
differences in Dex sensitivity are likely not due to T-cell
maturation status.
The adoptive transfer of Th17 in vitro polarized T-cells or
allergic airway disease elicited in Rorγt-overexpressing mice
consists of a Th17-predominate response that is also resistant
to treatment with Dex [18,32]. Because cytokines of the Th2
immune response are capable of influencing sensitivity to Dex
[59], we also sought to control for the possibility that the
presence of a Th2 response might impact Dex sensitivity. The
Dex sensitivity of the endogenously-generated Th17 response
did not change following inhibition of the generation of a Th2
response. Furthermore, IL-17A production by lung cells from
mice that received the adoptive transfer of in vitro polarized
Th2 cells and were then antigen challenged was also sensitive
to Dex treatment, demonstrating that in vitro culture prior to
adoptive transfer was not responsible for Dex-resistant IL-17
production. It is interesting that the Dex and anakinra sensitivity
profiles of restimulated lung cells following NO2-promoted
allergic sensitization and challenge matched closely with those
of the Th2 adoptive transfer. Considering that the STAT6-/-
mouse exhibited no pulmonary inflammation in our model, it
may be that the Th17 cytokine-producing cells in NO2-
promoted allergic airway disease are in fact Th2 cells [81]. A
recent article described that in vitro sensitivity to Dex can
recapitulate sensitivity in vivo, validating the functional
relevance of our approach [89]. Thus, the finding that the
endogenously-generated Th17 response is sensitive to Dex ex
vivo refutes the hypothesis that IL-17 contributes to Dex
resistance in vivo.
IL-23 and IL-17 have been demonstrated to increase the
expression of GC receptor beta, a dominant negative isoform
of the GC receptor, in PBMCs from healthy human donors [90],
thereby providing a mechanism through which these cytokines
can induce Dex resistance. On the other hand, IL-17 does not
necessarily correlate with Dex resistance in human samples
[91]. In mouse models of allergic airway disease, the few
studies reporting on Dex responsiveness of the endogenously-
generated Th17 response indicate that that it is Dex sensitive
[92-95]. RSV infection at the time of antigen challenge results
in increased levels of IL-17A and AHR development that is
exacerbated by Dex treatment, suggesting that in the context of
exacerbation, IL-17A may contribute to Dex resistance [25,96].
Similar to the Dex studies, blocking the Th2 response with
anti-IL-4 did not change the sensitivity of the endogenously-
generated Th17 response to treatment with anakinra. The
slight, albeit statistically significant, diminution in some Th17
cytokines by anakinra might have reflected the fact that while
the generation of in vitro polarized Th17 cells is independent of
IL-1R signaling, IL-1R signaling contributes to the expansion of
these cells [19]. Nonetheless, adoptive transfer of in vitro
polarized Th17 cells resulted in an anakinra-resistant
phenotype, indicating that the immune response generated in
vivo following Th17 adoptive transfer is likely independent of
IL-1R signaling.
Taken together, our data support a nonpathogenic role for
IL-17A and a protective role for the IL-1R-dependent Th17
adaptive immune response generated as a consequence of
NO2-promoted allergic airway disease. This response likely
does not contribute to glucocorticoid resistance in vivo.
Furthermore, the endogenously-generated Th17 response is
qualitatively distinct from that generated as a result of adoptive
transfer of in vitro polarized Th17 cells, both in its sensitivity to
GC and its requirement for IL-1R signaling. These data
demonstrate that the Th17 response generated endogenously
is substantially different than the response acquired upon
adaptive transfer of in vitro polarized Th17 cells and OVA
challenge, suggesting that in some instances, the outcomes of
an adoptive transfer study may not be generalizable to other
models of allergic airway disease. Clarification of where these
models fit in terms of clinical asthma demands robust
comparative analyses [97]. As exemplified by our findings, the
functional significance of the Th17 response in promoting
allergic airway disease is determined by the conditions in which
it was generated, ranging from protective to pathogenic. Given
the heterogeneity among patients with clinical asthma, the
contribution of a single type of immune response may also vary
among patients, which should be considered during
pharmacologic development and clinical testing [60].
Supporting Information
Figure S1.  NO2-dependent IgG exacerbation of AHR is
independent of the inflammatory response. Mice received
IgG isotype control antibody (1 mg in saline) one day prior to
NO2 exposure on day 0 and again one day prior to antigen
challenge on day 13, while NO2/O mice received no antibody.
Mice were exposed to NO2 on day 1 (NO2/O and IgG/NO 2/O
groups only). IgG/O mice received IgG antibody and were
exposed to OVA, but not NO2. Non-inflamed negative control
mice (non-inf) were naïve to antigen. All experimental groups
were exposed to OVA on days 1-3 and again during the
antigen challenge on days 14-16. 48 hours following the final
antigen challenge, methacholine responsiveness was
determined. Percent baseline and average percent baseline
per dose of methacholine were calculated for R (A-B) and E (C-
D). BAL total cells (E), macrophages (Macs; F), neutrophils
(PMNs; G), and eosinophils (Eos; H) were determined. Lungs
were removed, enzymatically digested, and restimulated for 96
hours in the presence of IgG alone (10 μg/mL), OVA, or IgG
and OVA for 96 hours prior to cytokine analysis by ELISA (I-K).
Statistics were performed by 2-way ANOVA (B and D) or 1-way
ANOVA (E-H) and Bonferroni post hoc analysis. **** p <
0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 compared to non-
inflamed unless otherwise indicated by brackets. ND, not
significantly different compared to non-inflamed, unless
otherwise indicated. n=6 (A-F) or n=3 (G-I) per group. The
dashed line in J and K represents the lower limit of quantitation
in the assays.
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Figure S2.  Increasing the dose of anakinra does not
significantly impact cytokine production by lung cells from
Th17 adoptively transferred and OVA challenged recipient
mice. CD4+ T-cells from OTII mice were either Th2 or Th17
polarized in vitro and adoptively transferred to recipient mice,
which were then OVA-challenged for 3 consecutive days and
analyzed 24 hours following the final OVA challenge. At
analysis, lungs were removed and enzymatically digested.
Lung single-cell suspensions were restimulated with OVA
antigen and incubated with increasing concentrations of
anakinra and Dex, as indicated. Cell supernatants were
harvested at 96 hours and analyzed for the production of
IL-17A (A) or IL-5 (B) by ELISA. Statistics were performed by
2-way ANOVA and Bonferroni post hoc analysis for cytokine
production resulting from increasing doses of anakinra. * p <
0.01 compared to the 0 μg/mL anakinra dose for that particular
dex dose; ◊ p < 0.05 compared to 0 M Dex for the indicated
anakinra dose; † p < 0.01 compared to 10-9 M Dex for the
indicated anakinra dose; ‡ p < 0.0001 compared to 10-8 M for
the indicated anakinra dose. For the Dex effect per dose of
anakinra, statistically significant decreases in cytokine
production are shown only for the corresponding 10-fold
increase in Dex concentration. The dashed line in A represents
the upper limit of detection of the assay. Samples from n = 4
mice were pooled prior to in vitro restimulation, which was
performed in triplicate.
(TIFF)
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